---
title: "Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Product information and disease description"
description: "Formulary evidence on Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Product information and disease description. Covers Product description and Place of product in therapy. 73 evidence topics quoted from 63 sources."
canonical: "https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/product-information-and-disease-description"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### FDA orphan designation and approval status

> “FDA Orphan Approval Status: Not FDA Approved for Orphan Indication”
> “Date Designated: 10/31/2012”

Source: [FDA Orphan Drug Designations and Approvals (2012)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=377912)

<a id="topic-2.1.1-2"></a>

##### Fast Track and Breakthrough Therapy designations

> “Fast Track Designation and Breakthrough Therapy Designation by the FDA in May 2019 and December 2019, respectively.”

Source: [Savara Inc. Form 10-K (2023)](https://www.sec.gov/Archives/edgar/data/1160308/000095017023010967/svra-20221231.htm)

<a id="topic-2.1.1-3"></a>

##### Initial biologics application and refusal to file

> “May 27, 2025”
> “the FDA determined that the BLA submitted in March 2025 was not sufficiently complete to permit substantive review”

Source: [Savara Inc. BLA refusal to file announcement (2025)](https://investors.savarapharma.com/news/news-details/2025/Savara-Receives-Refusal-to-File-RTF-Letter-From-the-U-S--Food-and-Drug-Administration-FDA-for-the-Biologics-License-Application-BLA-for-MOLBREEVI-to-Treat-Patients-With-Autoimmune-Pulmonary-Alveolar-Proteinosis-autoimmune-PAP/default.aspx)

<a id="topic-2.1.1-4"></a>

##### Regulatory status: Under review; BLA resubmitted December 2025 and accepted February 2026

> “In February 2026, the FDA formally filed the BLA for MOLBREEVI and granted Priority Review.”
> “constituted a major amendment to the BLA, resulting in a three-month extension of the Prescription Drug User Fee Act”
> “target action date to November 22, 2026”

Source: [Savara Inc. Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1160308/000119312526344585/svra-20260630.htm)

> “December 22, 2025”
> “resubmitted the MOLBREEVI BLA to the FDA, with Fujifilm as the drug substance manufacturer.”

Source: [Savara Inc. BLA resubmission announcement (2025)](https://investors.savarapharma.com/news/news-details/2025/Savara-Resubmits-the-Biologics-License-Application-BLA-to-the-U-S--Food-and-Drug-Administration-FDA-for-MOLBREEVI-for-the-Potential-Treatment-of-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP/default.aspx)

<a id="topic-2.1.1-5"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-6"></a>

##### Advisory Committee meeting

> “March 6, 2026”
> “an Advisory Committee meeting is not planned for the MOLBREEVI Biologics License Application (BLA)”

Source: [Savara Inc. MOLBREEVI regulatory update announcement (2026)](https://investors.savarapharma.com/news/news-details/2026/Savara-Provides-Regulatory-Update-on-the-MOLBREEVI-Development-Program-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP/default.aspx)

<a id="topic-2.1.1-7"></a>

##### Priority Review and extended FDA target action date

> “April 15, 2026”
> “Priority Review”
> “PDUFA target action date is November 22, 2026.”

Source: [Savara Inc. BLA review extension announcement (2026)](https://investors.savarapharma.com/news/news-details/2026/Savara-Announces-the-U-S--Food--Drug-Administration-FDA-Has-Extended-the-Review-Period-for-the-Molgramostim-Inhalation-Solution-Molgramostim-Biologics-License-Application-BLA-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP/default.aspx)

<a id="topic-2.1.1-8"></a>

##### European and United Kingdom regulatory applications

> “August 11, 2026”
> “MOLBREEVI MAAs Under Review by the EMA and the U.K.’s MHRA; Decisions Expected in Q1 2027 and Q4 2026, respectively”

Source: [Savara Inc. second quarter 2026 results announcement (2026)](https://investors.savarapharma.com/news/news-details/2026/Savara-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update/default.aspx)

<a id="topic-2.1.1-9"></a>

##### Approval status in the second-quarter business update

> “It is not approved in any indication.”

Source: [Savara Inc. second quarter 2026 results announcement (2026)](https://investors.savarapharma.com/news/news-details/2026/Savara-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update/default.aspx)

<a id="topic-2.1.1-10"></a>

##### European regulatory route in the horizon scan

> “Centralised (EMA)”

Source: [National Health Care Institute Horizonscan Geneesmiddelen (2026)](https://www.horizonscangeneesmiddelen.nl/geneesmiddelen/molgramostim?versie=versie-7)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Sponsor and generic name

> “Sponsor: Savara Inc.”
> “Generic Name: recombinant human GM-CSF, molgramostim”

Source: [FDA Orphan Drug Designations and Approvals (2012)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=377912)

<a id="topic-2.1.2.1-2"></a>

###### Manufacturer: Savara

> “Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF)”

Source: [Savara Inc. second quarter 2026 results announcement (2026)](https://investors.savarapharma.com/news/news-details/2026/Savara-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update/default.aspx)

<a id="topic-2.1.2.1-3"></a>

###### Proposed trade name and product name

> “MOLBREEVI”
> “molgramostim inhalation solution”

Source: [Savara Inc. investor relations home page](https://investors.savarapharma.com/)

<a id="topic-2.1.2.1-4"></a>

###### Therapeutic class

> “inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF)”

Source: [Savara Inc. investor relations home page](https://investors.savarapharma.com/)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### IMPALA-2 investigational formulation

| Attribute | Reported value |
| --- | --- |
| Dosage form | “Nebulizer solution” |
| Concentration | “250 µg/mL” |

Source: [ClinicalTrials.gov NCT04544293 protocol](https://cdn.clinicaltrials.gov/large-docs/93/NCT04544293/Prot_000.pdf)

<a id="topic-2.1.2.2-2"></a>

###### IMPALA-X investigational product storage

> “24 August 2018”
> “The IMP must be stored at 2-8°C.”
> “The IMP should not be frozen or shaken”

Source: [ClinicalTrials.gov NCT03482752](https://cdn.clinicaltrials.gov/large-docs/52/NCT03482752/Prot_000.pdf)

<a id="topic-2.1.2.2-3"></a>

###### Material safety data sheet

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### ATC classification

| Attribute | Reported value |
| --- | --- |
| Code | “L03AA03” |
| Substance | “molgramostim” |
| Class | “Colony stimulating factors” |

Source: [WHO Collaborating Centre for Drug Statistics Methodology (2026)](https://atcddd.fhi.no/atc_ddd_index/?code=L03AA03)

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Indication under development

> “Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).”

Source: [Savara Inc. investor relations home page](https://investors.savarapharma.com/)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Proposed restoration of alveolar macrophage function

> “We believe that inhalation of MOLBREEVI activates macrophages in the lung alveoli, thus potentially restoring the surfactant-clearing activity of the alveolar macrophages”

Source: [Savara Inc. MOLBREEVI in autoimmune PAP page](https://savarapharma.com/our-science/what-is-apap/clinical-trials-in-apap/molbreevi-in-apap/)

<a id="topic-2.1.2.6.1-2"></a>

###### GM-CSF regulation of surfactant homeostasis and host defense

> “In the lungs, GM-CSF regulates surfactant homeostasis and lung host defense through innate immune function.”

Source: [McCarthy et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12582097/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Healthy volunteers: blood leukocyte response

> “a rapid increase in white blood cells (WBC) counts and leucocyte subsets”

Source: [Trapnell et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12458661/)

Additional sources: [Luisetti et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/20728558/)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Healthy volunteers: systemic exposure and elimination

> “In healthy people, inhaled molgramostim was well-tolerated and resulted in systemic exposure at picogram levels, which had the expected PD effects on blood leucocyte levels that mostly remained within normal ranges.”
> “42 subjects were enrolled”
> “peaked at 2 hours for all three doses and had an elimination half-life of 1.7±0.0 to 5.9±0.9 hours”

Source: [Trapnell et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12458661/)

<a id="topic-2.1.2.6.3-2"></a>

###### Healthy volunteers: exposure proportionality

> “Systemic GM-CSF exposure was non-linear”

Source: [Trapnell et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12458661/)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Pregnancy and breastfeeding: IMPALA-2 exclusions

> “Pregnant and breastfeeding women will not be included”

Source: [ClinicalTrials.gov NCT04544293 protocol](https://cdn.clinicaltrials.gov/large-docs/93/NCT04544293/Prot_000.pdf)

<a id="topic-2.1.2.8-2"></a>

###### Adolescent case report

> “We here describe a unique case of a 14-year-old patient who was successfully treated with WLL and subsequent inhalations with molgramostim”

Source: [Gajewska et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5925949/)

<a id="topic-2.1.2.8-3"></a>

###### Renal impairment

No evidence found.

<a id="topic-2.1.2.8-4"></a>

###### Hepatic impairment

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Molgramostim

No evidence found.

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Molgramostim on Other Drugs

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### IMPALA-2 investigational dose

> “300 µg in 1.2 mL, daily”

Source: [ClinicalTrials.gov NCT04544293 protocol](https://cdn.clinicaltrials.gov/large-docs/93/NCT04544293/Prot_000.pdf)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Investigational nebulizer system

> “Molgramostim is delivered via a proprietary investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of molgramostim.”

Source: [Savara Inc. ERS 2026 encore presentations announcement (2026)](https://investors.savarapharma.com/news/news-details/2026/Savara-Announces-Encore-Presentations-of-Results-from-the-Phase-3-Clinical-Trial-of-Molgramostim-Inhalation-Solution-Molgramostim-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-APAP-at-the-European-Respiratory-Society-ERS-Congress-2026/default.aspx)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Anticipated specialty pharmacy distribution and patient assistance

> “PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*”
> “If approved,”
> “comprehensive financial and insurance assistance.”

Source: [Savara Inc. PANTHERx Rare specialty pharmacy announcement (2026)](https://investors.savarapharma.com/news/news-details/2026/PANTHERx-Rare-Selected-by-Savara-as-the-U-S--Exclusive-Specialty-Pharmacy-for-MOLBREEVI/default.aspx)

<a id="topic-2.1.2.11-2"></a>

###### Expanded access program authorization

> “The Savara Early Access Program has been reviewed and allowed to proceed by the U.S. Food and Drug Administration (FDA)”

Source: [Savara Inc. (2024)](https://investors.savarapharma.com/news/news-details/2024/Savara-Announces-Expanded-Access-Program-EAP-for-Molgramostim-Inhalation-Solution-Molgramostim-for-Patients-with-Autoimmune-Pulmonary-Alveolar-Proteinosis-aPAP-09-27-2024/default.aspx)

<a id="topic-2.1.2.11-3"></a>

###### Expanded access requests

> “All requests must be submitted by a licensed pulmonologist.”
> “Requests for access are not a guarantee that access to molgramostim will be granted.”

Source: [Savara Inc. expanded access policy](https://savarapharma.com/development/expanded-access-policy/)

<a id="topic-2.1.2.11-4"></a>

###### Expanded access dosing and follow-up

> “Patients will dose molgramostim nebulizer solution 300 micrograms (mcg) once daily and be followed by their physician every 3 months”

Source: [ClinicalTrials.gov NCT06546098](https://clinicaltrials.gov/study/NCT06546098)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### IMPALA-2 supplemental oxygen

> “Oxygen supplementation may be considered necessary for subject safety and well-being”

Source: [ClinicalTrials.gov NCT04544293 protocol](https://cdn.clinicaltrials.gov/large-docs/93/NCT04544293/Prot_000.pdf)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Molgramostim on Quality Measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Sargramostim and molgramostim: limits of indirect comparisons

> “these results are exploratory and do not prove clinical equivalency between sargramostim and molgramostim”
> “No significant differences were found for six-minute walk distance”

Source: [Naeem et al. (2026)](https://link.springer.com/article/10.1186/s12890-026-04179-1)

<a id="topic-2.1.2.14-2"></a>

###### Daratumumab in refractory disease: case report

> “One year post completion of Daratumumab, the patient remained in remission with clinical and radiological improvement.”

Source: [Strong et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12174958/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Surfactant accumulation in autoimmune pulmonary alveolar proteinosis

> “Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli (or air sacs) of the lungs.”

Source: [Savara Inc. (2024)](https://investors.savarapharma.com/news/news-details/2024/Savara-Announces-Expanded-Access-Program-EAP-for-Molgramostim-Inhalation-Solution-Molgramostim-for-Patients-with-Autoimmune-Pulmonary-Alveolar-Proteinosis-aPAP-09-27-2024/default.aspx)

Additional sources: [Trapnell et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30846703/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Autoimmune pulmonary alveolar proteinosis

<a id="topic-2.2.1.2.1-1"></a>

###### Japanese registry: minimum incidence and prevalence

> “Autoimmune PAP represented 89.9% of cases and had a minimum incidence and prevalence of 0.49 and 6.2 per million, respectively.”

Source: [Inoue et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2720118/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Autoimmune pulmonary alveolar proteinosis

<a id="topic-2.2.1.2.2-1"></a>

###### United States claims analysis: all PAP subtypes

> “2018”
> “The annual prevalence of PAP in the general population was 6.87 ±0.33 per million”
> “likely a minimum estimate of true prevalence”

Source: [McCarthy et al. (2018)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-018-0846-y)

<a id="topic-2.2.1.2.2-2"></a>

###### Updated United States claims-based autoimmune PAP population estimate

> “September 2, 2025”
> “Autoimmune PAP prevalence rates were applied to the confirmed PAP population”
> “resulting in ~5,500 autoimmune PAP patients in the U.S.”

Source: [Savara Inc. health claims analysis announcement (2025)](https://investors.savarapharma.com/news/news-details/2025/Savara-Announces-New-U-S--Health-Claims-Data-Analysis-Finds-Over-50-Increase-in-the-Estimated-Number-of-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP-Patients-Compared-to-Previous-Claims-Analysis/default.aspx)

<a id="topic-2.2.1.2.2-3"></a>

###### Japanese registry: smoking and dust exposure

> “a Japanese national registry”
> “A history of smoking occurred in 56%, and dust exposure occurred in 23%; instances of familial onset did not occur.”

Source: [Inoue et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2720118/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Spontaneous improvement

> “Spontaneous improvement may occur in 8–25% of cases”

Source: [Jouneau et al. (2025)](https://link.springer.com/article/10.1007/s40265-025-02228-3)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### GM-CSF autoantibodies

> “Pathogenesis is driven by GM-CSF (granulocyte/macrophage colony-stimulating factor) autoantibodies, which are present at high concentrations in blood and tissues”

Source: [McCarthy et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9851473/)

Additional sources: [Futami et al. (2026)](https://www.nature.com/articles/s41467-026-74717-2)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Serum GM-CSF neutralizing autoantibodies

> “Detection of GM-CSF neutralizing autoantibodies in serum confirms autoimmune PAP and rules out other causes.”

Source: [Bonella and Borie (2025a)](https://pubmed.ncbi.nlm.nih.gov/41110926/)

<a id="topic-2.2.1.5-2"></a>

###### Dried blood spot card autoantibody testing

> “30 autoimmune PAP patients and 19 healthy people”
> “the sensitivity and specificity of the DBSC GMAb test were both 100%”

Source: [Carey et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10026347/)

<a id="topic-2.2.1.5-3"></a>

###### Immunochromatographic anti-GM-CSF autoantibody testing

> “211 APAP and 171 non-APAP cases.”

Source: [Narita et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12865520/)

<a id="topic-2.2.1.5-4"></a>

###### Exploratory biomarker study population

> “Overall, 144 individuals were enrolled”

Source: [Campo et al. (2022)](https://www.nature.com/articles/s41598-022-11446-8)

<a id="topic-2.2.1.5-5"></a>

###### Diagnostic assay clinical accuracy

> “Clinical accuracy achieved 100% in a cohort of 40 subjects that utilized a cut-off value of 8.0 μg/mL”

Source: [Kim et al. (2024)](https://savarapharma.com/wp-content/uploads/Poster-1.pdf)

<a id="topic-2.2.1.5-6"></a>

###### Diagnostic pathways and delays

> “Patients reported heterogeneous and indirect diagnostic pathways, often waiting months or years for the correct diagnosis.”

Source: [Ataya et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39947303/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Respiratory symptoms: dyspnea, cough, and sputum production

> “Common symptoms of autoimmune PAP”
> “Shortness of breath”
> “Cough”
> “Sputum production”

Source: [Savara Inc. autoimmune PAP disease page](https://savarapharma.com/our-science/what-is-apap/)

<a id="topic-2.2.1.6-2"></a>

###### Functional symptoms: fatigue and reduced exercise capacity

> “Fatigue”
> “Reduced exercise capacity”

Source: [Savara Inc. autoimmune PAP disease page](https://savarapharma.com/our-science/what-is-apap/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Progression to pulmonary fibrosis

> “a quarter of aPAP patients progressed towards pulmonary fibrosis.”

Source: [Guirriec et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11610044/)

<a id="topic-2.2.1.7-2"></a>

###### Infectious complications

> “We included 104 patients”
> “Thirty-five (34%) patients were hospitalised due to infection.”

Source: [Mabo et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37758458/)

Additional sources: [Akasaka et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26264717/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Autoimmune pulmonary alveolar proteinosis

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Reported burden of current treatments and off-label therapies

> “burdensome, emotionally taxing, and/or financially worrisome.”

Source: [Ataya et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39947303/)

Additional sources: [McCarthy et al. (2026a)](https://publications.ersnet.org/content/errev/35/180/250237)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### United States claims analysis: PAP and matched-control cohorts

| Measure | PAP cohort | Control cohort |
| --- | --- | --- |
| Participants | “2312” | “9247” |
| Average charges during follow-up, mean ± standard deviation | “$71,672.64 ± $226,117.54” | “$14,655.91 ± $74,791.03” |

Source: [Lee et al. (2025)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-024-03478-2)

<a id="topic-2.2.1.8.2-2"></a>

###### Hospital admissions: nationwide inpatient sample

> “average cost of admission was $29,932.20 (CI 13,739-46,124).”

Source: [Kim et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9509629/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Autoimmune pulmonary alveolar proteinosis on Families

No evidence found.

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Serum GM-CSF autoantibody testing: qualitative cost rationale

> “can reduce the cost and morbidity associated with more invasive testing such as lung biopsies”

Source: [Lee et al. (2025)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-024-03478-2)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Whole Lung Lavage

<a id="topic-2.2.2.1.1-1"></a>

###### Historical standard of care

> “The current standard-of-care is a Whole Lung Lavage (WLL)”

Source: [Savara Inc. autoimmune PAP disease page](https://savarapharma.com/our-science/what-is-apap/)

<a id="topic-2.2.2.1.1-2"></a>

###### First-line treatment recommendations

> “Whole lung lavage and inhaled GM-CSF are first-line treatments for symptomatic or progressive aPAP.”

Source: [Alfaro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12070199/)

<a id="topic-2.2.2.1.1-3"></a>

###### Restoration of alveolar function without cure

> “Whole lung lavage can effectively restore the alveolar function, but not cure the disease.”

Source: [Bonella and Borie (2025a)](https://pubmed.ncbi.nlm.nih.gov/41110926/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Inhaled Granulocyte-Macrophage Colony-Stimulating Factor

<a id="topic-2.2.2.1.2-1"></a>

###### ERS recommendation for symptomatic autoimmune PAP

> “We recommend inhaled GM-CSF for symptomatic patients with confirmed autoimmune PAP.”
> “(Strong recommendation, very low certainty of evidence.)”

Source: [European Respiratory Society](https://publications.ersnet.org/content/erj/64/5/2400725)

<a id="topic-2.2.2.1.2-2"></a>

###### Meta-analysis: DLCO percent predicted

> “Inhaled GM-CSF significantly enhanced DLCO% predicted (MD 5.09; 95% CI 2.05 to 8.13; p = 0.001; I² = 0%)”

Source: [Dang et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42045620/)

<a id="topic-2.2.2.1.2-3"></a>

###### Nebulized GM-CSF systematic review: serious adverse events

> “No serious trial-related adverse events were reported.”

Source: [Munsif et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10663936/)

<a id="topic-2.2.2.1.2-4"></a>

###### Sargramostim after whole lung lavage

> “This long-term, prospective, randomised trial demonstrated inhaled sargramostim following WLL reduced the requirement for WLL, improved lung function and was safe in aPAP patients.”

Source: [Campo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10764982/)

<a id="topic-2.2.2.1.2-5"></a>

###### Mild-to-moderate disease trial: primary endpoint

> “We found no significant response in the primary endpoint”

Source: [Tian et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7330972/)

<a id="topic-2.2.2.1.2-6"></a>

###### Long-term inhaled GM-CSF: relapse during dose de-escalation

> “Two patients relapsed at de-escalating doses.”

Source: [Papiris et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24890235/)

Additional sources: [Chen et al. (2025a)](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1552566/full); [Chen et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40529121/); [Sheng et al. (2018)](https://link.springer.com/article/10.1186/s12931-018-0862-4); [Tazawa et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31483963/); [Higgins et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42466621/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 B-cell Depletion with Rituximab

<a id="topic-2.2.2.1.3-1"></a>

###### Options for refractory disease

> “Rituximab, plasmapheresis, and lung transplantation are options for refractory disease.”

Source: [Alfaro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12070199/)

Additional sources: [Kavuru et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21478218/); [Soyez et al. (2018)](https://link.springer.com/article/10.1186/s12931-018-0780-5)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Plasmapheresis

<a id="topic-2.2.2.1.4-1"></a>

###### Options for refractory disease

> “Rituximab, plasmapheresis, and lung transplantation are options for refractory disease.”

Source: [Alfaro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12070199/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Lung Transplantation

<a id="topic-2.2.2.1.5-1"></a>

###### Options for refractory disease

> “Rituximab, plasmapheresis, and lung transplantation are options for refractory disease.”

Source: [Alfaro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12070199/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Supportive Care and Exposure Reduction

<a id="topic-2.2.2.1.6-1"></a>

###### Respiratory supportive care and exposure reduction

> “respiratory rehabilitation, oxygen supplementation, and palliative care.”
> “smoking cessation and avoidance of dust inhalation”

Source: [Jouneau et al. (2025)](https://link.springer.com/article/10.1007/s40265-025-02228-3)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Limitations of Current Therapies

<a id="topic-2.2.2.1.7-1"></a>

###### Summary

Whole lung lavage can restore alveolar function but does not cure the disease. The ERS recommendation for inhaled GM-CSF is strong, but its stated evidence certainty is very low. Relapse during inhaled GM-CSF dose de-escalation has been reported. Indirect comparisons of sargramostim and molgramostim are exploratory and do not establish clinical equivalence.

Source: [Bonella and Borie (2025a)](https://pubmed.ncbi.nlm.nih.gov/41110926/); [European Respiratory Society](https://publications.ersnet.org/content/erj/64/5/2400725); [Papiris et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24890235/); [Naeem et al. (2026)](https://link.springer.com/article/10.1186/s12890-026-04179-1)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

Guideline-based first-line options for symptomatic or progressive autoimmune pulmonary alveolar proteinosis are whole lung lavage and inhaled GM-CSF. The studied molgramostim regimen is 300 µg daily using a dedicated investigational eFlow nebulizer system. Expanded access requests must come from a licensed pulmonologist and do not guarantee treatment access. Savara has selected an exclusive U.S. specialty pharmacy, with commercial distribution and patient assistance contingent on approval.

Source: [Alfaro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12070199/); [ClinicalTrials.gov NCT04544293 protocol](https://cdn.clinicaltrials.gov/large-docs/93/NCT04544293/Prot_000.pdf); [Savara Inc. ERS 2026 encore presentations announcement (2026)](https://investors.savarapharma.com/news/news-details/2026/Savara-Announces-Encore-Presentations-of-Results-from-the-Phase-3-Clinical-Trial-of-Molgramostim-Inhalation-Solution-Molgramostim-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-APAP-at-the-European-Respiratory-Society-ERS-Congress-2026/default.aspx); [Savara Inc. expanded access policy](https://savarapharma.com/development/expanded-access-policy/); [Savara Inc. PANTHERx Rare specialty pharmacy announcement (2026)](https://investors.savarapharma.com/news/news-details/2026/PANTHERx-Rare-Selected-by-Savara-as-the-U-S--Exclusive-Specialty-Pharmacy-for-MOLBREEVI/default.aspx)

Additional sources: [Lettieri et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39142709/); [Jehn and Bonella (2023)](https://pubmed.ncbi.nlm.nih.gov/37395514/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### IMPALA-2 treatment effect across baseline DLCO subgroups

> “For DLCO%, the magnitude of the treatment effect was similar across DLco% subgroups at 24 and 48 weeks”

Source: [McCarthy (2025b)](https://savarapharma.com/wp-content/uploads/Efficacy-of-Inhaled-Molgramostim-According-to-Severity-of-Autoimmune-Pulmonary-Alveolar-Proteinosis-aPAP.pdf)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Referral for diagnostic and therapeutic guidance

> “Referral to expert centres is advised for diagnostic and therapeutic guidance.”

Source: [Alfaro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12070199/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Molgramostim: proposed therapeutic goals

> “is believed to help restore the surfactant-clearing activity of macrophages, thus improving oxygenation, lung function, and health-related quality of life (HRQoL).”

Source: [Savara Inc. PANTHERx Rare specialty pharmacy announcement (2026)](https://investors.savarapharma.com/news/news-details/2026/PANTHERx-Rare-Selected-by-Savara-as-the-U-S--Exclusive-Specialty-Pharmacy-for-MOLBREEVI/default.aspx)

<a id="topic-2.2.2.7-2"></a>

###### Outcomes and outcome measures: scoping review

> “31 distinct outcomes and 92 corresponding outcome measures.”

Source: [Xiong et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12871052/)

## Related pages
- [Molgramostim Inhalation Solution: Autoimmune pulmonary alveolar proteinosis](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Terms and abbreviations](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/terms-and-abbreviations.md)
- [Molgramostim Inhalation Solution: Autoimmune pulmonary alveolar proteinosis](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/executive-summary.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Clinical evidence](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/clinical-evidence.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Economic information and modeling report](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/economics) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/economics.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: References](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/references) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/references.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: prevalence by geography](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/prevalence) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/prevalence.md)
- [Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/cost-effectiveness-analyses.md)
